TapewireFind a company

person · Reporting owner

Lim Jonathan E

Disclosed activity across 4 companies

Tapewire entity
38112
SEC CIK
0001283290

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Boundless Bio, Inc.BOLD · Entity 7063DirectorJune 15, 2026June 15, 2026
Erasca, Inc.ERAS · Entity 3796Director · Chairman & CEO · 10% ownerJanuary 29, 2026January 30, 2026
Maze Therapeutics, Inc.MAZE · Entity 1775DirectorJune 08, 2026June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Boundless Bio, Inc.

Report date June 15, 2026 · Filed June 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2036-06-14Direct48,000 Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-15 · Grant · Acquired 48,000 · Balance 48,000

F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

Erasca, Inc.

Report date January 29, 2026 · Filed January 30, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.31 · Expires 2036-01-29Direct2,000,000 Reported balance After 2026-01-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-29 · Grant · Acquired 2,000,000 · Balance 2,000,000

F1: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date.

Maze Therapeutics, Inc.

Report date June 08, 2026 · Filed June 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07Direct18,000 Reported balance After 2026-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000

F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ignyta, Inc.

Report date February 08, 2018 · Filed February 12, 2018

Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-02-08 transaction · row 1
1 source row

Row 1 · 2018-02-08 · Disposition to issuer · Disposed 179,661 · Balance 0

F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").

Common StockSEC Table I · non-derivativeIndirectBy City Hill Venture Partners I, LLC0 Reported balance After 2018-02-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2018-02-08 · Disposition to issuer · Disposed 3,350,000 · Balance 0

F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").

F2: The Reporting Person is the Manager of City Hill Ventures, LLC, which is the Manager of City Hill Ventures Partners I, LLC, and as such the Reporting Person and City Hill Ventures, LLC have the power to vote or dispose of the securities held of record by the Reporting Person and may be deemed to beneficially own those securities. The Reporting Person disclaims beneficial ownership of the securities held of record by the City Hill Venture Partners I, LLC except to the extent of his pecuniary interest therein.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-16Direct0 Reported balance After 2018-02-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-02-08 · Disposition to issuer · Disposed 400,000 · Balance 0

F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.58 · Expires 2015-01-07Direct0 Reported balance After 2018-02-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2018-02-08 · Disposition to issuer · Disposed 100,000 · Balance 0

F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04Direct0 Reported balance After 2018-02-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-02-08 · Disposition to issuer · Disposed 120,000 · Balance 0

F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").

F2: The Reporting Person is the Manager of City Hill Ventures, LLC, which is the Manager of City Hill Ventures Partners I, LLC, and as such the Reporting Person and City Hill Ventures, LLC have the power to vote or dispose of the securities held of record by the Reporting Person and may be deemed to beneficially own those securities. The Reporting Person disclaims beneficial ownership of the securities held of record by the City Hill Venture Partners I, LLC except to the extent of his pecuniary interest therein.

F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 15, 2026 Filed Jun 15, 2026 23:36 UTC Boundless Bio, Inc. BOLD · Entity 7063 GrantStock Option (right to buy) · Derivative 48,000 $0.00 Strike: $1.40 $0.00
Disclosure

SEC source: 0001193125-26-271465 · ownership.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2036-06-14

F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:28 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $23.58 $0.00
Disclosure

SEC source: 0001283290-26-000002 · form4-06102026_080618.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2036-06-07

F1 · derivative.exercise_date: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

Read SEC document
January 29, 2026 Filed Jan 30, 2026 14:05 UTC Erasca, Inc. ERAS · Entity 3796 GrantStock option (right to buy) · Derivative 2,000,000 $0.00 Strike: $10.31 $0.00
Disclosure

SEC source: 0001193125-26-030626 · ownership.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 2,000,000 shares

Expires 2036-01-29

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date.

Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:17 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $23.67 $0.00
Disclosure

SEC source: 0001283290-25-000005 · form4-09242025_080917.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-09-21

F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

Read SEC document
June 23, 2025 Filed Jun 23, 2025 21:13 UTC Boundless Bio, Inc. BOLD · Entity 7063 GrantStock Option (right to buy) · Derivative 24,000 $0.00 Strike: $1.03 $0.00
Disclosure

SEC source: 0000950170-25-089077 · ownership.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2035-06-22

F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionSeries B Preferred Stock · Derivative 2,231,381 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 5

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 270,232 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.

F3 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.

F3 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.

F3 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.

F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionSeries A Preferred Stock · Derivative 363,703 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 4

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 37,724 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.

F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.

F1 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.

F1 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.

F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionCommon Stock 270,232 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · nonDerivative · entry 2

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · City Hill, LLC

Disclosed balance after: 307,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.

F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.

Read SEC document
February 03, 2025 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 ConversionCommon Stock 37,724 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · City Hill, LLC

Disclosed balance after: 37,724

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.

F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 14:15 UTC Erasca, Inc. ERAS · Entity 3796 GrantStock option (right to buy) · Derivative 2,500,000 $0.00 Strike: $1.76 $0.00
Disclosure

SEC source: 0000950170-25-014192 · ownership.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2035-02-02

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2025, subject to the Reporting Person's continuous service to the issuer on each such vesting date.

Read SEC document
December 09, 2024 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 GrantStock Option (Right to Buy) · Derivative 9,086 $0.00 Strike: $10.42 $0.00
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 8

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,086

Underlying: Common Stock · 9,086 shares

Expires 2034-12-08

F4 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.

F7 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Read SEC document
December 09, 2024 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 Disposition to issuerStock Option (Right to Buy) · Derivative 5,704 Not disclosed Strike: $17.74 Not disclosed
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 7

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,704 shares

Expires 2033-03-08

F4 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.

F6 · price: This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price.

F5 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Read SEC document
December 09, 2024 Filed Feb 4, 2025 21:37 UTC Maze Therapeutics, Inc. MAZE · Entity 1775 GrantStock Option (Right to Buy) · Derivative 5,704 Not disclosed Strike: $10.42 Not disclosed
Disclosure

SEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 6

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,704

Underlying: Common Stock · 5,704 shares

Expires 2033-03-08

F4 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.

F6 · price: This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price.

F5 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Read SEC document
June 20, 2024 Filed Jun 20, 2024 23:49 UTC Boundless Bio, Inc. BOLD · Entity 7063 GrantStock Option (Right to Buy) · Derivative 6,610 $0.00 Strike: $5.50 $0.00
Disclosure

SEC source: 0000950170-24-075800 · ownership.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,610

Underlying: Common Stock · 6,610 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2024 Incentive Award Plan. The stock option vests in 36 substantially equal monthly installments beginning on the first monthly anniversary of June 20, 2024, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
June 20, 2024 Filed Jun 21, 2024 12:47 UTC Erasca, Inc. ERAS · Entity 3796 GrantStock Option (right to buy) · Derivative 632,759 $0.00 Strike: $2.03 $0.00
Disclosure

SEC source: 0001209191-24-005924 · doc4.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 632,759

Underlying: Common Stock · 632,759 shares

Expires 2034-06-19

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on June 20, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:30 UTC Boundless Bio, Inc. BOLD · Entity 7063 ConversionSeries C Convertible Preferred Stock · Derivative 7,326 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-041843 · ownership.xml · derivative · entry 5

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 7,326 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:30 UTC Boundless Bio, Inc. BOLD · Entity 7063 ConversionSeries B Convertible Preferred Stock · Derivative 5,128 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-041843 · ownership.xml · derivative · entry 4

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 5,128 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:30 UTC Boundless Bio, Inc. BOLD · Entity 7063 ConversionSeries A Convertible Preferred Stock · Derivative 512,820 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-041843 · ownership.xml · derivative · entry 3

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 512,820 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:30 UTC Boundless Bio, Inc. BOLD · Entity 7063 ConversionCommon Stock 525,274 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-041843 · ownership.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 550,915

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 20:30 UTC Boundless Bio, Inc. BOLD · Entity 7063 GrantStock Option · Derivative 13,219 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0000950170-24-038705 · ownership.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,219

Underlying: Common Stock · 13,219 shares

Expires 2034-03-26

F1 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on April 27, 2024.

Read SEC document
February 05, 2024 Filed Feb 7, 2024 23:54 UTC Erasca, Inc. ERAS · Entity 3796 GrantStock Option (right to buy) · Derivative 1,500,000 $0.00 Strike: $1.70 $0.00
Disclosure

SEC source: 0001209191-24-002968 · doc4.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500,000

Underlying: Common Stock · 1,500,000 shares

Expires 2034-02-04

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 00:41 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 278,150 $1.72 $478,418.00
Disclosure

SEC source: 0001209191-23-057681 · doc4.xml · nonDerivative · entry 2

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 12,899,360

F1 · balance_after: Includes purchases made on December 5, 2023, and December 6, 2023 that are reported on this Form 4.

F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
December 05, 2023 Filed Dec 7, 2023 00:41 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 721,850 $1.69 $1,217,760.95
Disclosure

SEC source: 0001209191-23-057681 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 12,899,360

F1 · balance_after: Includes purchases made on December 5, 2023, and December 6, 2023 that are reported on this Form 4.

F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
October 05, 2023 Filed Oct 10, 2023 12:00 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 1,000,000 $2.03 $2,026,000.00
Disclosure

SEC source: 0001209191-23-052403 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Jonathan E. Lim and Conyee T. lim Family Trust, dated April 28, 2005

Disclosed balance after: 19,456,216

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
June 08, 2023 Filed Jun 9, 2023 00:54 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 100,000 $2.75 $275,000.00
Disclosure

SEC source: 0001209191-23-035590 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 18,396,216

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
March 28, 2023 Filed Mar 29, 2023 01:24 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 100,000 $2.84 $284,000.00
Disclosure

SEC source: 0001209191-23-021458 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 18,296,216

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 13:55 UTC Erasca, Inc. ERAS · Entity 3796 GrantStock Option (right to buy) · Derivative 1,500,000 $0.00 Strike: $4.00 $0.00
Disclosure

SEC source: 0001209191-23-006482 · doc4.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

Underlying: Common Stock · 1,500,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
January 10, 2023 Filed Jan 10, 2023 21:46 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 60,000 $3.86 $231,420.00
Disclosure

SEC source: 0001209191-23-002802 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 20,256,222

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
December 14, 2022 Filed Dec 15, 2022 16:53 UTC Erasca, Inc. ERAS · Entity 3796 PurchaseCommon Stock 40,000 $4.99 $199,600.00
Disclosure

SEC source: 0001209191-22-061352 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 20,196,222

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
November 30, 2022 Filed Feb 16, 2023 01:55 UTC Erasca, Inc. ERAS · Entity 3796 GiftCommon Stock 2,000,006 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-005182 · doc5.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 18,196,216

F1 · kind: Transfer of shares to a trust of which the children of the Reporting Person and his spouse are beneficiaries.

F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
February 01, 2022 Filed Feb 4, 2022 00:51 UTC Erasca, Inc. ERAS · Entity 3796 GrantStock Option (Right to Buy) · Derivative 791,000 $0.00 Strike: $11.54 $0.00
Disclosure

SEC source: 0001209191-22-007062 · doc4.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 791,000

Underlying: Common Stock · 791,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Read SEC document
July 20, 2021 Filed Jul 21, 2021 00:58 UTC Erasca, Inc. ERAS · Entity 3796 ConversionSeries B-2 Preferred Stock · Derivative 112,000 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 6

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 93,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
July 20, 2021 Filed Jul 21, 2021 00:58 UTC Erasca, Inc. ERAS · Entity 3796 ConversionSeries B-1 Preferred Stock · Derivative 336,000 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 5

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 280,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
July 20, 2021 Filed Jul 21, 2021 00:58 UTC Erasca, Inc. ERAS · Entity 3796 ConversionSeries A Preferred Stock · Derivative 6,081,233 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 4

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 0

Underlying: Common Stock · 5,067,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
July 20, 2021 Filed Jul 21, 2021 00:58 UTC Erasca, Inc. ERAS · Entity 3796 ConversionSeries A Preferred Stock · Derivative 6,162,468 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 3

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 0

Underlying: Common Stock · 5,135,390 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
July 20, 2021 Filed Jul 21, 2021 00:58 UTC Erasca, Inc. ERAS · Entity 3796 ConversionCommon Stock 5,441,027 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-029085 · doc4.xml · nonDerivative · entry 2

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill, LLC

Disclosed balance after: 11,899,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein.

Read SEC document
July 20, 2021 Filed Jul 21, 2021 00:58 UTC Erasca, Inc. ERAS · Entity 3796 ConversionCommon Stock 5,135,390 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-029085 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner

Lim Conyee T. · CIK 0001872346 · 10% owner

City Hill, LLC · CIK 0001872305 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005

Disclosed balance after: 20,156,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005.

Read SEC document
February 08, 2018 Filed Feb 12, 2018 20:33 UTC Ignyta, Inc. RXDX · Entity 169521 Disposition to issuerStock Option (Right to Buy) · Derivative 120,000 $0.00 Strike: $5.60 $0.00
Disclosure

SEC source: 0001209191-18-009148 · doc4.xml · derivative · entry 5

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 120,000 shares

Expires 2027-01-04

F3 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Read SEC document
February 08, 2018 Filed Feb 12, 2018 20:33 UTC Ignyta, Inc. RXDX · Entity 169521 Disposition to issuerStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $6.58 $0.00
Disclosure

SEC source: 0001209191-18-009148 · doc4.xml · derivative · entry 4

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2015-01-07

F3 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Read SEC document
February 08, 2018 Filed Feb 12, 2018 20:33 UTC Ignyta, Inc. RXDX · Entity 169521 Disposition to issuerStock Option (Right to Buy) · Derivative 400,000 $0.00 Strike: $6.00 $0.00
Disclosure

SEC source: 0001209191-18-009148 · doc4.xml · derivative · entry 3

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 400,000 shares

Expires 2023-12-16

F3 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

Read SEC document
February 08, 2018 Filed Feb 12, 2018 20:33 UTC Ignyta, Inc. RXDX · Entity 169521 Disposition to issuerCommon Stock 3,350,000 $27.00 $90,450,000.00
Disclosure

SEC source: 0001209191-18-009148 · doc4.xml · nonDerivative · entry 2

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By City Hill Venture Partners I, LLC

Disclosed balance after: 0

F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").

F2 · ownership.nature: The Reporting Person is the Manager of City Hill Ventures, LLC, which is the Manager of City Hill Ventures Partners I, LLC, and as such the Reporting Person and City Hill Ventures, LLC have the power to vote or dispose of the securities held of record by the Reporting Person and may be deemed to beneficially own those securities. The Reporting Person disclaims beneficial ownership of the securities held of record by the City Hill Venture Partners I, LLC except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2018 Filed Feb 12, 2018 20:33 UTC Ignyta, Inc. RXDX · Entity 169521 Disposition to issuerCommon Stock 179,661 $27.00 $4,850,847.00
Disclosure

SEC source: 0001209191-18-009148 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").

Read SEC document
December 26, 2017 Filed Dec 29, 2017 02:34 UTC Ignyta, Inc. RXDX · Entity 169521 Tax withholdingCommon Stock 19,006 $26.70 $507,460.20
Disclosure

SEC source: 0000899243-17-029701 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · President, CEO and Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,661

Read SEC document
December 22, 2017 Filed Dec 23, 2017 02:47 UTC Ignyta, Inc. RXDX · Entity 169521 GrantCommon Stock 68,334 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-067162 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,667

F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date.

Read SEC document
December 22, 2017 Filed Dec 28, 2017 00:49 UTC Amendment Ignyta, Inc. RXDX · Entity 169521 GrantCommon Stock 68,334 $0.00 $0.00
Disclosure

SEC source: 0000899243-17-029643 · doc4a.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,667

F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date.

Read SEC document
February 13, 2017 Filed Mar 11, 2017 01:05 UTC Ignyta, Inc. RXDX · Entity 169521 Exercise / conversionStock Option (Right to Buy) · Derivative 6,945 $0.00 Strike: $0.60 $0.00
Disclosure

SEC source: 0001209191-17-019996 · doc4.xml · derivative · entry 3

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,945 shares

Expires 2023-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 13, 2017 Filed Mar 11, 2017 01:05 UTC Ignyta, Inc. RXDX · Entity 169521 Exercise / conversionCommon Stock 6,945 $0.60 $4,167.00
Disclosure

SEC source: 0001209191-17-019996 · doc4.xml · nonDerivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 05, 2017 Filed Jan 6, 2017 23:51 UTC Ignyta, Inc. RXDX · Entity 169521 GrantStock Option (Right to Buy) · Derivative 120,000 $0.00 Strike: $5.60 $0.00
Disclosure

SEC source: 0001209191-17-002767 · doc4.xml · derivative · entry 1

Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2027-01-04

F1 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on January 5, 2018, and 1/48th of the shares subject to the option vest monthly thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.